Cooperative interactions of HER-2 and HPV-16 oncoproteins in the malignant transformation of human mammary epithelial cells

Neoplasia

Volumn 7, Issue 8, 2005, Pages 788-798

  Woods Ignatoski, Kathleen M ^a   Dziubinski, Michele L ^a   Ammerman, Cheryl ^a   Ethier, Stephen P ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b KARMANOS CANCER INSTITUTE   (United States)

Author keywords

EGFR; Her 2; HPV E6; HPV E7; Human breast cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; E6 PROTEIN, HUMAN PAPILLOMAVIRUS TYPE 16; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ONCOGENE PROTEIN E7, HUMAN PAPILLOMAVIRUS TYPE 16; ONCOPROTEIN; REPRESSOR PROTEIN;

ARTICLE; BREAST EPITHELIUM; CANCER GROWTH; CELL PROLIFERATION; DRUG INHIBITION; DRUG MECHANISM; ELECTROPHORETIC MOBILITY; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; PRIORITY JOURNAL; PROTEIN EXPRESSION; BIOSYNTHESIS; BREAST TUMOR; CELL LINE; CELL TRANSFORMATION; EPITHELIUM CELL; MAMMARY GLAND; METABOLISM;

BREAST NEOPLASMS; CELL LINE, TRANSFORMED; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; EPIDERMAL GROWTH FACTOR; EPITHELIAL CELLS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MAMMARY GLANDS, HUMAN; ONCOGENE PROTEINS, VIRAL; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2; REPRESSOR PROTEINS;

EID: 33644698719     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.05106     Document Type: Article

References (52)

1. Thor AD, Liu S, Edgerton S, Moore D II, Kasowitz KM, Benz CC, Stern DF, and DiGiovanna MP (2000). Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. J Clin Oncol 18, 3230-3239.
2. Tsuda HH (2001). Prognostic and predictive value of c-erbB-2 (HER2/neu) gene amplification in human breast cancer. Breast Cancer 8, 38-44.
3. Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SAW, Killander D, and McGuire WL (1990). HER2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50, 4332-4337.
4. Marte BM, Grausporta D, Jeschke M, Fabbro D, Hynes NE, and Taverna D (1995). NDF/heregulin activates MAP kinase and p70/p85 S6 kinase during proliferation or differentiation of mammary epithelial cells. Oncogene 10, 167-175.
5. Beerli RR, Grausporta D, Woodscook K, Chen XM, Yarden Y, and Hynes NE (1995). Neu differentiation factor activation of ErbB-3 and ErbB-4 is cell specific and displays a differential requirement for ErbB-2. Mol Cell Biol 15, 6496-6505.
6. Karunagaran D, Tzahar E, Beerli RR, Chen XM, Grausporta D, Ratzkin BJ, Seger R, Hynes NE, and Yarden Y (1996). ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer. EMBO J 15, 254-264.
7. Pinkaskramarski R, Soussan L, Waterman H, Levkowitz G, Alroy I, Klapper L, Lavi S, Seger R, Ratzkin BJ, Sela M, et al. (1996). Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15, 2452-2467.
8. Tzahar E, Waterman H, Chen X, Levkowitz G, Karunagaran D, Lavi S, Ratzkin B, and Yarden Y (1996). A hierarchical network of inter-receptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol 16, 5276-5287.
9. GrausPorta D, Beerli RR, Daly JM, and Hynes NE (1997). ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling. EMBO J 16, 1647-1655.
10. Alroy I and Yarden Y (1997). The erbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand - receptor interactions. FEBS Lett 410, 83-86.
11. Olayioye MA, Graus-Porta D, Beerli RR, Rohrer J, Gay B, and Hynes NE (1998). ErbB-1 and ErbB-2 acquire distinct signaling properties dependent upon their dimerization partner. Mol Cell Biol, 5042-5051.
12. Klapper LN, Glathe S, Vaisman N, Hynes NE, Andrews GC, Sela M, and Yarden Y (1999). The ErbB-2/HER2 oncoprotein of human carcinomas may function solely as a shared coreceptor for multiple stroma - derived growth factors. Proc Natl Acad Sci USA 96, 4995-5000.
13. Daly JM, Olayioye MA, Wong AM, Neve R, Lane HA, Maurer FG, and Hynes NE (1999). NDF/heregulin - induced cell cycle changes and apoptosis in breast tumour cells: role of PI3 kinase and p38 MAP kinase pathways. Oncogene 18, 3440-3451.
14. Holbro T, Beerli RR, Maurer F, Koziczak M, Barbas CF III, and Hynes NE (2003). The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. PNAS 100, 8933-8938.
15. Hammond SL, Ham RG, and Stampfer MR (1984). Serum-free growth of human mammary epithelial cells: rapid clonal growth in defined medium and extended serial passage with pituitary extract. Proc Natl Acad Sci USA 81, 5435-5439.
16. Ethier SP (1985). Primary culture and serial passage of normal and carcinogen-treated rat mammary epithelial cells in vitro. J Natl Cancer Inst 74, 1307-1318.
17. Ethier SP, Summerfelt RM, Cundiff KC, and Asch BB (1990). The influence of growth factors on the proliferative potential of normal and primary breast cancer - derived human breast epithelial cells. Breast Cancer Res Treat 17, 221-230.
18. Stampfer MR, Pan CH, Hosoda J, Bartholomew J, Mendelsohn J, and Yaswen P (1993). Blockage of EGF receptor signal transduction causes reversible arrest of normal and immortal human mammary epithelial cells with synchronous reentry into the cell cycle. Exp Cell Res 208, 175-188.
19. Ram TG, Kokeny KE, Dilts CA, and Ethier SP (1995). Mitogenic activity of neu differentiation factor/heregulin mimics that of epidermal growth factor and insulin-like growth factor-I in human mammary epithelial cells. J Cell Physiol 163, 589-596.
20. Gollahon LS and Shay JW (1996). Immortalization of human mammary epithelial cells transfected with mutant p53 (273(his)). Oncogene 12, 715-725.
21. Wright WE, Brasiskyte D, Piatyszek MA, and Shay JW (1996). Experimental elongation of telomeres extends the lifespan of immortal x normal cell hybrids. EMBO J 15, 1734-1741.
22. Ethier SP and Cundiff KC (1987). Importance of extended growth potential and growth factor independence on tial in vivo neoplastic potential of primary rat mammary carcinoma cells. Cancer Res 47, 5316-5322.
23. Ethier SP, Moorthy R, and Dilts CA (1991). Secretion of an epidermal growth factor - like growth factor by epidermal growth factor - independent rat mammary carcinoma cells. Cell Growth Differ 2, 593-602.
24. Ethier SP, Langton BC, and Dilts CA (1996). Growth factor independent proliferation of rat mammary carcinoma cells by autocrine secretion of neu-differentiation factor/heregulin and transforming growth factor alpha. Mol Carcinog 15, 134-143.
25. Ram TG, Dilts CA, Dziubinski ML, Pierce LJ, and Ethier SP (1996). Insulin-like growth factor and epidermal growth factor independence in human mammary carcinoma cells with c-erbB-2 gene amplification and progressively elevated levels of tyrosine phosphorylated erbB-2. Mol Carcinog 15, 227-2386.
26. Woods Ignatoski KM, LaPointe AJ, Radany EH, and Ethier SP (1999). ErbB-2 overexpression in human mammary epithelial cells confers growth factor independence. Endocrinology 140, 3615-3622.
27. Woods Ignatoski KM, Maehama T, Markwart SM, Dixon JE, Livant DL, and Ethier SP (2000). ERBB-2 overexpression confers PI 3′-kinase - dependent invasion capacity on human mammary epithelial cells. Br J Cancer 82, 666-674.
28. Jia Y, Markwart SM, Gransden LA, Woods Ignatoski KM, Ethier SP, and Livant DL (2004). Integrin receptors regulate MMP1 dependent invasion by breast cancer cells and by mammary epithelial cells. Cancer Res 64, 8674-8681.
29. Chau BN and Wang JYJ (2003). Coordinated regulation of life and death by Rb. Nat Rev Cancer 3, 130-138.
30. Sherr CJ (2004). Principles of tumor suppression. Cell 116, 235-246.
31. Yokouchi M, Kondo T, Houghton A, Bartkiewicz M, Horne WC, Zhang H, Yoshimura A, and Baron R (1999). Ligand-induced ubiquitination of the epidermal growth factor receptor involves the interaction of the c-Cbl RING finger and UbcH7. J Biol Chem 274, 31707-31712.
32. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, and Arteaga CL (2001). Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2) - overexpressing breast cancer cells in vitro and in vivo. Cancer Res 61, 8887-8895.
33. Moasser M, Basso A, Averbuch SD, and Rosen N (2001). The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 61, 7184-7188.
34. Anido J, Matar P, Albanell J, Guzmán M, Rojo F, Arribas J, Averbuch S, and Baselga J (2003). ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 9, 1274-1283.
35. Lebeau A, Unholzer A, Amann G, Kronawitter M, Bauerfeind I, Sendelhofert A, Iff A, and Löhrs U (2003). EGFR, HER2/neu, Cyclin D1, p21 and p53 in correlation to cell proliferation and steroid hormone receptor status in ductal carcinoma in situ of the breast. Breast Cancer Res Treat 79, 187-198.
36. Hudelist G, Singer CF, Manavi M, Pischinger K, Kubista E, and Czerwenka K (2003). Co-expression of ErbB-family members in human breast cancer: HER2/neu is the preferred dimerization candidate in nodal-positive tumors. Breast Cancer Res Treat 80, 353-361.
37. Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, and Nesland JM (2002). EGFR family expression in breast carcinomas. c-erbB-2 and c-erbB-4 receptors have different effects on survival. J Pathol 196, 17-25.
38. Bull SB, Ozcelik H, Pinnaduwage D, Blackstein ME, Sutherland DAJ, Pritchard KI, Tzontcheva AT, Sidlofsky S, Hanna WM, Qizilbash AH, et al. (2004). The combination of p53 mutation and neu/erbB-2 amplification is associated with poor survival in node-negative breast cancer. J Clin Oncol 22, 86-96.
39. Charafe-Jauffret E, Tarpin C, Bardou V-J, Bertucci F, Ginestier C, Braud A-C, Puig B, Geneix J, Hassoun J, Birnbaum D, et al. (2004). Immunophenotypic analysis of inflammatory breast cancers: identification of an "inflammatory signature". J Pathol 202, 265-273.
40. Woods Ignatoski KM, Livant DL, Markwart S, Grewal NK, and Ethier SP (2003). The role of PI3′ kinase and its downstream signals in erbB-2 - mediated transformation. Mol Cancer Res 1, 551-560.
41. Woods Ignatoski KM, Livant DL, Grewal NK, Markwart S, and Ethier SP (2003). p38MAPK induces cell surface a4 integrin down-regulation to facilitate erbB-2 - mediated invasion. Neoplasia 5, 128-134.
42. Hendriks BS, Opresko LK, Wiley HS, and Lauffenburger D (2003). Quantitative analysis of HER2-mediated effects on HER2 and epidermal growth factor receptor endocytosis: distribution of homo- and heterodimers depends on relative HER2 levels. J Biol Chem 278, 23343-23351.
43. Moustafa A-EA, Foulkes WD, Benlimame N, Wong A, Yen L, Bergeron G, Batist G, Alpert L, and Alaoui-Jamali MA (2004). E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells. Oncogene 23, 350-358.
44. Helt A-M and Galloway DA (2003). Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis 24, 159-169.
45. Winters ZE, Leek RD, Bradburn MJ, Norbury CJ, and Harris AL (2003). Cytoplasmic p21WAF1/CIP1 expression is correlated with HER2/ neu in breast cancer and is an independent predictor of prognosis. Br Cancer Res 5, R242-R249.
46. Alkarain A, Jordan R, and Slingerland J (2004). p27 deregulation in breast cancer: prognostic significance and implications for therapy. J Mammary Gland Biol Neoplasia 9, 67-80.
47. Jares P, Fernandez PL, Campo E, Nadal A, Bosch F, Aiza G, Nayach I, Traserra J, and Cardesa A (1994). Prad-1/cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res 54, 4813-4817.
48. Lukas J, Aagaard L, Strauss M, and Bartek J (1995). Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res, 4818-4823.
49. Michalides R, Hageman P, Vantinteren H, Houben L, Wientjens E, Klompmaker R, and Peterse J (1996). A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 73, 728-734.
50. Fredersdorf S, Burns J, Milne AM, Packham G, Fallis L, Gillett CE, Royds JA, Peston D, Hall PA, Hanby AM, et al. (1997). High level expression of p27(kip1) and cyclin D1 in some human breast cancer cells: inverse correlation between the expression of p27(kip1) and degree of malignancy in human breast and colorectal cancers. Proc Natl Acad Sci USA 94, 6380-6385.
51. Lodén M, Stighall M, Nielsen NH, Roos G, Emdin SO, Östlund H, and Landberg G (2002). The cyclin D1 high and cyclin E high subgroups of breast cancer: separate pathways in tumorigenesis based on pattern of genetic aberrations and inactivation of the pRb node. Oncogene 21, 4680-4690.
52. Fung YK and T'Ang A (1992). The role of the retinoblastoma gene in breast cancer development. Cancer Treat Res 61, 59-68.